Early-generation kinase medicines are limited by poor selectivity, off-target effects and the emergence of resistance.

Our founding scientists envisioned a new generation of highly selective kinase medicines that could prolong lives, improve quality of life and prevent disease recurrences, with more potent target inhibition, fewer off-target effects and opportunities for therapeutic combinations.

They worked to build a scalable platform that could yield multiple selective kinase medicines for a wide range of diseases, bringing this innovation to as many patients as possible.

A look inside our labs

Our scientists merge expertise in bioinformatics and structural and cell biology, world-class drug design capabilities and a proprietary library of novel compounds to create a new discovery paradigm. This unique approach enables us to rapidly identify compelling disease targets and design highly selective kinase medicines.

The result is a robust and diverse portfolio of clinical- and research-stage programs targeting genomically defined cancers, rare diseases and cancer immunotherapy. With a steadfast commitment to scientific excellence and to patients, we aim to rapidly and unequivocally change the face of medicine.

Meet our Scientists


Dilinie P. Fernando: Scientist II, Medicinal Chemistry

My path

I earned a B.S. in Chemistry from North Dakota State and a M.S. in Organic Chemistry from Washington State University.

My experience

My desire to bring transformative medicines to patients led me to Blueprint Medicines. Prior to joining Blueprint, I worked on kinase inhibitors for the treatment of amyotrophic lateral sclerosis (ALS) and irritable bowel syndrome (IBS) at Amgen Discovery Cambridge and at Pfizer Global Research in Groton, where my efforts contributed to multiple clinical drug candidates. This experience is helping me bring new clinical candidates to patients in need at Blueprint.

My biggest achievement

My career started at Abbott (now Abbvie) in North Chicago, working on process research for clinical candidates from gram to multi kilogram scale. It was my good fortune to have worked in the only operational pilot plant owned by large pharma in the US. One of my most impactful contributions was the design and execution of a novel route to a Phase 2 clinical compound at Abbott. I performed the catalyst screen and route optimization for the first large scale coupling of an unsymmetrical urea to an aryl halide utilizing palladium catalyzed cross-coupling on pilot plant scale (64Kg scale).

My recent scientific publications

“Discovery of PF-06835919: A Potent Inhibitor of Ketohexokinase (KHK) for the Treatment of Metabolic Disorders Driven by the Overconsumption of Fructose,” published in the Journal of Medicinal Chemistry in 2020

“Optimizing the Benefit/Risk of Acetyl-CoA Carboxylase Inhibitors through Liver Targeting,” published in the Journal of Medicinal Chemistry in 2020

“Discovery and Preclinical Characterization of 6-Chloro-5-[4-(1-hydroxycyclobutyl)phenyl]-1H-indole-3-carboxylic Acid (PF-06409577), a Direct Activator of Adenosine Monophosphate-activated Protein Kinase (AMPK), for the Potential Treatment of Diabetic Nephropathy,” published in the Journal of Medicinal Chemistry in 2016

“Route Selection and Optimization in the Synthesis of Two Imidazopyridine Inhibitors of DGAT-2,” published in Organic Process Research & Development in 2018

“Discovery and in Vitro Optimization of 3-Sulfamoylbenzamides as ROMK Inhibitors,” published in ACS Medicinal Chemistry Letters in 2018

See Dilinie's other publications

My Blueprint Medicines

Blueprint’s excellence in the precision oncology space targeting kinases was the primary driver, but seeing the beautiful lab space during my first visit to Blueprint was the deal-closer. I love the Blueprint vibe, culture and vision as small teams take on big dreams to serve patients with unmet medical needs.

Marion Dorsch: Chief Scientific Officer

My path

I earned an M.S. and a Ph.D. in Biology from the Free University of Berlin, Germany.

My Ph.D. thesis was focused on stimulating the anti-tumor immune response  through intratumoral cytokine expression.

My experience

After completing my postdoctoral research at Columbia University, I came to Cambridge, MA and joined Millennium Pharmaceuticals. I then went on to Novartis Institutes of Biomedical Research, Sanofi, and Agios Pharmaceuticals—all in Cambridge—before joining Blueprint in 2016.

My biggest achievement

During my time at Novartis, I led efforts to target the Hedgehog pathway, a developmental  pathway mutated in medulloblastoma and basal carcinoma. My team discovered and developed a small-molecule antagonist of Hedgehog signaling that ultimately became a treatment of metastatic basal cell carcinoma under the trade name ODOMZO®. In parallel we also elucidated novel resistance mechanisms to Hedgehog pathway inhibition and identified additional indications for hedgehog pathway antagonists. Our work was published in high-impact journals.

My recent scientific publications

Co-author, “AG-221, a first-in-class therapy targeting acute myeloid leukemia harboring oncogenic IDH2 mutations”, published in Cancer Discovery in 2017

Co-author, “Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation”, published in Science in 2013

Senior author, “Loss of the tumor suppressor Snf5 leads to aberrant activation of the Hedgehog-Gli pathway”, published in Nature Medicine in 2010

Senior author, “Targeting resistance to Smoothened antagonists by inhibiting the PI3K pathway”, published in Science Translational Medicine in 2010

Senior author, “Discovery of NVP-LDE225, a potent and selective biphenyl-3-carboxamide Smoothened antagonist”, published in ACS Medicinal Chemistry Letters in 2010

See Marion's other publications

My Blueprint Medicines

Our discovery platform –and our immensely talented cross-functional team –empowers us to pursue targets of interest quickly and nimbly. As a result, we’ve been able to deliver multiple clinical programs with proof-of-concept in defined patient populations and a strong portfolio of discovery programs. As a scientist, I find that incredibly motivating.

Chaoyang Ye: Head of Computational Biology & Bioinformatics

My path

I earned a B.S. in Biochemistry from Nanjing University, and a Ph.D. in Microbiology from the University of Missouri-Columbia.

My experience

As a graduate student at the University of Missouri, I studied viral molecular genetics (working in the laboratory of Dr. David Pintel), and completed postgraduate work in genomics at the University of Pennsylvania. At the Allen Institute for Brain Science in Seattle, my team developed novel single cell technologies to study neural differentiation. In 2013, I came to Cambridge to join Novartis, where as a laboratory head I utilized cutting-edge screening and genomics technologies to model neurological diseases before joining Blueprint Medicines in 2018.

My biggest achievement

I was part of an international collaboration to sequence the first two ant genomes and use them as model organisms to study aging. This led to co-first authored papers in Science and Genome Research in 2010 and 2013, respectively.

My recent scientific publications

“Genome-Scale CRISPR Screens Identify Human Pluripotency-Specific Genes,” published in Cell Reports in 2019.

“p53 inhibits CRISPR-Cas9 engineering in human pluripotent stem cells,” published in Nature Medicine in 2018.

“DRUG-seq for miniaturized high-throughput transcriptome profiling in drug discovery,” published in Nature Communication in 2018.

See Chaoyang's other publications

My Blueprint Medicines

I joined Blueprint when I realized that my knowledge of genomics and data analytics might have a profound impact on patients’ lives. Each day I work with diverse teams, all dedicated to an expansive project portfolio, and a vast store of data that we can analyze to potentially discover new treatment advances.


“We’re entering a new era of precision medicine… we can now rapidly and reproducibly design potent and selective kinase medicines for previously undruggable as well as newly discovered drivers of disease. Combined with recent advances in molecular profiling, we believe these next-generation kinase medicines can quickly achieve clinical proof-of-concept and, ultimately, transform patient care.”

Marion Dorsch, Ph.D., Chief Scientific Officer

Scientific Advisory Board

Giulio Draetta, M.D., Ph.D.

Director, Institute for Applied Cancer Science at MD Anderson Cancer Center, and Professor of Molecular and Cellular Oncology

Brian Druker, M.D.*

Director, Oregon Health & Science University Knight Cancer Institute, and JELD-WEN Chair of Leukemia Research

Carlos Garcia-Echeverria, Ph.D.

Global Head of Research Platforms, Sanofi

Scott Lowe, Ph.D.*

Member, Cancer Biology and Genetics Program at Memorial Sloan Kettering Institute Cancer Center, and Chair, Geoffrey Beene Cancer Research Center

Nick Lydon, Ph.D.*

Founder, Granite Biopharma LLC

Charles L. Sawyers, M.D.*

Director, Human Oncology and Pathogenesis Program at Memorial Sloan-Kettering Cancer Center